Catalent Invests $350m In Bloomington As Recipharm Ties Up Deals
Multi-Year Investment Delivers On Catalent Promise To Continue Expansion
Executive Summary
In the burgeoning biologics CDMO space, Catalent has announced further investment at its flagship campus in Bloomington, Indiana, while Recipharm has wrapped up a pair of deals that will beef up the Sweden-based firm’s presence in the US.
You may also be interested in...
Manufacturing Roundup – 17 January 2019
Dr Reddy’s is hit with a manufacturing setback after getting issued a Form 483 report for its site in Andhra Pradesh, India, while several firms announce site expansions, including in Spain and the US.
AMR Industry Alliance Publishes Manufacturing Standard
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.
Cigna: US Adalimumab Prices Could Vary Meaningfully
Cigna has responded to several questions from the insurer/payer side on the potential effect of multiple biosimilar Humira products launching in 2023 and beyond.